GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Biote Corp (NAS:BTMD) » Definitions » Earnings Yield %

Biote (BTMD) Earnings Yield % : 1.64% (As of Jun. 05, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biote Earnings Yield %?

The earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

As of today (2024-06-05), the stock price of Biote is $6.70. Biote's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.11. Therefore, Biote's earnings yield of today is 1.64%.

The earnings yield does not consider the growth of the business. A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Biote's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Biote Earnings Yield % Calculation

Earnings yield is the reciprocal of the P/E Ratio.

Biote's Earnings Yield for today is calculated as

Earnings Yield=Earnings per Share (Diluted) (TTM)/Share Price
=0.110/6.70
=1.64 %

Biote's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.110 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Earnings Yield=Net Income /Market Cap

The earnings in the calculation is the Trailing Twelve Months earnings.


Biote  (NAS:BTMD) Earnings Yield % Explanation

If the P/E ratio is an indication of how many years it takes for the company to earn back the stock price shareholders pay to buy the shares, the earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

If a company loses money, the earnings yield is negative. This gives a more straightforward indication that the company is losing money. This is an advantage of using earnings yield instead of the P/E ratio in valuation. For valuation purposes, the P/B Ratio and the P/S Ratio should be used for companies that are losing money.

Like the P/E ratio, the earnings yield can be used to compare investments in different industries. It can even be used to compare the attractiveness of different asset classes such as bonds and cash. Of course, the earnings yield should not be the only factor in deciding which asset classes to invest.

Also similar to the P/E ratio, the earnings yield does not consider the growth of the business. A growing company with the same earnings yield should be more attractive than a company that has the same earnings yield but does not grow.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %.

Be Aware

Just like the P/E Ratio, non-recurring items such as selling part of the business, selling a previous investment, etc., can affect earnings yield dramatically. The earning yield is also a poor indication for cyclical companies. When a cyclical stock has a high earnings yield it is usually at the peak of its cycle.


Biote Earnings Yield % Related Terms

Thank you for viewing the detailed overview of Biote's Earnings Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biote (BTMD) Business Description

Traded in Other Exchanges
N/A
Address
1875 West Walnut Hill Lane, Suite 100, Irving, TX, USA, 75038
Biote Corp is engaged in bioidentical hormone replacement optimization platform and complementary nutraceutical business. The company offers end-to-end platform that provides practitioners with medical education, training and certification, practice management software, and digital and point-of-care marketing support.
Executives
Mary Elizabeth Conlon officer: General Counsel C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Anil K Shrivastava 10 percent owner 200 PARK AVENUE, 17TH FLOOR, NEW YORK NY 10016
Michael David Braner 10 percent owner 200 PARK AVENUE, 17TH FLOOR, NEW YORK NY 10016
Daniel M. Friedberg 10 percent owner C/O SAGARD CAPITAL, 325 GREENWICH AVENUE, GREENWICH CT 06830
325 Capital Llc 10 percent owner 757 THIRD AVENUE, 20TH FLOOR, NEW YORK NY 10017
Mary Joan Puncochar officer: Chief Commercial Officer C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Roystone Capital Holdings Llc 10 percent owner 767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Roystone Capital Management Lp 10 percent owner 780 THIRD AVENUE, 41ST FLOOR, NEW YORK NY 10017
Samar Jagat Kamdar officer: Chief Financial Officer 7042 CORONADO AVE., DALLAS TX 75214
Marc D Beer director C/O AEGERION PHARMACEUTICALS, 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960
Guines Llc 10 percent owner 767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Richard R Barrera 10 percent owner 767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Debra L Morris director 11620 WILSHIRE BOULEVARD, SUITE 1000, LOS ANGELES CA 90025
Andrew R Heyer director, officer: President and Director 501 MADISON AVENUE, FLOOR 5, NEW YORK NY 10019
Teresa Sue Weber director, officer: Chief Executive Officer C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038

Biote (BTMD) Headlines

From GuruFocus

Biote to Participate at Upcoming Investor Conferences

By Business Wire Business Wire 05-31-2023

Biote to Present at 35th Annual Roth Conference

By Business Wire Business Wire 03-02-2023

Biote Announces Pricing of Secondary Offering of Common Stock

By Business Wire Business Wire 06-05-2023

Biote Appoints Ross W. McQuivey, M.D. as Chief Medical Officer

By Business Wire Business Wire 06-16-2022

Biote Announces Pricing of Secondary Offering of Common Stock

By Business Wire Business Wire 01-05-2023

Biote Appoints Debby Morris to Board of Directors

By Business Wire Business Wire 11-07-2022